Literature DB >> 3208840

Ro 15-4513, like anxiogenic beta-carbolines, increases dopamine metabolism in the prefrontal cortex of the rat.

O Giorgi1, M G Corda, G Biggio.   

Abstract

The effects of Ro 15-4513, FG 7142 and beta-CCM on the activity of the mesocortical dopaminergic system were examined by measuring the changes in the content of the principal dopamine (DA) metabolite, dihydroxyphenylacetic acid (DOPAC) in the prefrontal cortex of the rat. Ro 15-4513 increased the DOPAC content in the prefrontal cortex in a dose-dependent manner (5-40 mg/kg i.p.) but had no effect on DA concentrations. A similar increase in DOPAC content was induced by FG 7142 (40 mg/kg i.p.) and beta-CCM (8 mg/kg s.c.), two beta-carboline derivatives that interact with benzodiazepine recognition sites as partial inverse agonists. These effects of Ro 15-4513, FG 7142 and beta-CCM on DA metabolism in the prefrontal cortex are mediated via benzodiazepine recognition sites, since they were prevented by the administration of the benzodiazepine antagonists Ro 15-1788 and ZK 93426. These data indicate that Ro 15-4513 is an inverse agonist at benzodiazepine recognition sites.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208840     DOI: 10.1016/0014-2999(88)90148-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Benzodiazepine prevention of swim stress-induced sensitization of cortical biogenic amines: an in vivo microdialysis study.

Authors:  F Petty; S Jordan; G L Kramer; P K Zukas; J Wu
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

2.  GABA(A) receptors containing (alpha)5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry.

Authors:  H L June; S C Harvey; K L Foster; P F McKay; R Cummings; M Garcia; D Mason; C Grey; S McCane; L S Williams; T B Johnson; X He; S Rock; J M Cook
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.